Background A previous analysis in this trial showed that among patients with severe,
symptomatic aortic stenosis who were at low surgical risk, the rate of the composite end …

A recent 3-year analysis of the Medtronic Evolut Transcatheter Aortic Valve Replacement in
Low Risk Patients trial (NCT02701283) demonstrated sustained valve performance and …

Abstract Background and Aims Transcatheter aortic valve implantation (TAVI) has become a
viable treatment option for patients with severe aortic valve stenosis across a broad range of …

The medical technology sector is characterised by a constant influx of innovations with the
potential to revolutionise patient care. In France, there are several pathways for medical …

Transcatheter aortic valve replacement (TAVR) has emerged as a ground‐breaking,
minimally invasive alternative to traditional open‐heart surgery, primarily designed for …

Background The use of transcatheter aortic valve replacement for severe aortic stenosis in
low-risk patients necessitates an evaluation of contemporary long-term, real-world outcomes …

BACKGROUND: The optimal treatment in patients with severe aortic stenosis and small
aortic annulus (SAA) remains to be determined. This study aimed to compare the …

The long-term safety and effectiveness of transcatheter aortic valve replacement (TAVR)
compared with surgical aortic valve replacement (SAVR) in low surgical risk has not been …

Abstract Background and Aims Transcatheter aortic valve implantation (TAVI) has become
the first choice to treat older patients with severe symptomatic aortic stenosis (AS). This study …

Surgical aortic valve replacement (SAVR) has long been the standard treatment for severe
symptomatic aortic stenosis (AS). However, transcatheter aortic valve replacement (TAVR) …